Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021

A SARS-CoV-2 P.1 (Gamma) variant outbreak occurred at a skilled nursing facility in Washington, USA, in April 2021. Effectiveness of 2 doses of mRNA vaccines against P.1 infection among residents in this outbreak was 75.0% (95% CI 44.5%–88.7%), similar to effectiveness for other pre-Delta variants a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, James W., Loughran, Julie, Deng, Li, Varghese, Jasmine, Clark, Shauna, Harrison, Casandra, Gacetta, Molly, Jernigan, John A., Fleming-Dutra, Katherine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622236/
https://www.ncbi.nlm.nih.gov/pubmed/36170764
http://dx.doi.org/10.3201/eid2811.221043
_version_ 1784821716422230016
author Lewis, James W.
Loughran, Julie
Deng, Li
Varghese, Jasmine
Clark, Shauna
Harrison, Casandra
Gacetta, Molly
Jernigan, John A.
Fleming-Dutra, Katherine E.
author_facet Lewis, James W.
Loughran, Julie
Deng, Li
Varghese, Jasmine
Clark, Shauna
Harrison, Casandra
Gacetta, Molly
Jernigan, John A.
Fleming-Dutra, Katherine E.
author_sort Lewis, James W.
collection PubMed
description A SARS-CoV-2 P.1 (Gamma) variant outbreak occurred at a skilled nursing facility in Washington, USA, in April 2021. Effectiveness of 2 doses of mRNA vaccines against P.1 infection among residents in this outbreak was 75.0% (95% CI 44.5%–88.7%), similar to effectiveness for other pre-Delta variants among long-term care residents.
format Online
Article
Text
id pubmed-9622236
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-96222362022-11-05 Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021 Lewis, James W. Loughran, Julie Deng, Li Varghese, Jasmine Clark, Shauna Harrison, Casandra Gacetta, Molly Jernigan, John A. Fleming-Dutra, Katherine E. Emerg Infect Dis Research Letter A SARS-CoV-2 P.1 (Gamma) variant outbreak occurred at a skilled nursing facility in Washington, USA, in April 2021. Effectiveness of 2 doses of mRNA vaccines against P.1 infection among residents in this outbreak was 75.0% (95% CI 44.5%–88.7%), similar to effectiveness for other pre-Delta variants among long-term care residents. Centers for Disease Control and Prevention 2022-11 /pmc/articles/PMC9622236/ /pubmed/36170764 http://dx.doi.org/10.3201/eid2811.221043 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Lewis, James W.
Loughran, Julie
Deng, Li
Varghese, Jasmine
Clark, Shauna
Harrison, Casandra
Gacetta, Molly
Jernigan, John A.
Fleming-Dutra, Katherine E.
Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021
title Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021
title_full Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021
title_fullStr Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021
title_full_unstemmed Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021
title_short Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021
title_sort vaccine effectiveness against sars-cov-2 variant p.1 in nursing-facility residents, washington, usa, april 2021
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622236/
https://www.ncbi.nlm.nih.gov/pubmed/36170764
http://dx.doi.org/10.3201/eid2811.221043
work_keys_str_mv AT lewisjamesw vaccineeffectivenessagainstsarscov2variantp1innursingfacilityresidentswashingtonusaapril2021
AT loughranjulie vaccineeffectivenessagainstsarscov2variantp1innursingfacilityresidentswashingtonusaapril2021
AT dengli vaccineeffectivenessagainstsarscov2variantp1innursingfacilityresidentswashingtonusaapril2021
AT varghesejasmine vaccineeffectivenessagainstsarscov2variantp1innursingfacilityresidentswashingtonusaapril2021
AT clarkshauna vaccineeffectivenessagainstsarscov2variantp1innursingfacilityresidentswashingtonusaapril2021
AT harrisoncasandra vaccineeffectivenessagainstsarscov2variantp1innursingfacilityresidentswashingtonusaapril2021
AT gacettamolly vaccineeffectivenessagainstsarscov2variantp1innursingfacilityresidentswashingtonusaapril2021
AT jerniganjohna vaccineeffectivenessagainstsarscov2variantp1innursingfacilityresidentswashingtonusaapril2021
AT flemingdutrakatherinee vaccineeffectivenessagainstsarscov2variantp1innursingfacilityresidentswashingtonusaapril2021

Ejemplares similares